
LSTA Stock Forecast & Price Target
LSTA Analyst Ratings
Bulls say
Lisata Therapeutics Inc. has demonstrated promising advancements in its investigational drug, certepetide, particularly highlighted by positive overall survival trends and four complete responses observed in a recent study cohort. The encouraging data from Cohort B indicate that a second dose of certepetide may enhance progression-free survival (PFS) and overall response rate (ORR) in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC). This clinical progress positions the company favorably within the pharmaceutical sector, underscoring its potential for significant contributions to cancer treatment solutions.
Bears say
Lisata Therapeutics Inc faces significant risks that could adversely impact its stock performance, primarily due to the uncertainty surrounding the success of its investigational product, certepetide, in clinical trials. The company could struggle to secure the necessary funding to continue developing its candidate therapies, which poses a threat to its operational capabilities. In addition, any failed or inconclusive clinical trials could further stagnate progress, limiting the potential for future commercialization and undermining confidence in the company's strategic outlook.
This aggregate rating is based on analysts' research of Lisata Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
LSTA Analyst Forecast & Price Prediction
Start investing in LSTA
Order type
Buy in
Order amount
Est. shares
0 shares